FORWARD-LOOKING AND CAUTIONARY STATEMENTS

Transcription

1 INVESTOR PRESENTATION January 2013

2 KP TISSUE INC. KP Tissue was created to acquire, and its business is limited to holding, an equity interest in Kruger Products LP (KPLP). KP Tissue trades on the TSX under the symbol KPT. 2

3 FORWARD-LOOKING AND CAUTIONARY STATEMENTS This Presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for any securities nor shall it or any part of it form the basis of or be relied on in connection with, or act as any inducement to enter into, any contract or commitment whatsoever. Recipients of this Presentation who are considering acquiring securities of KP Tissue Inc. (the Corporation or KPT ) are reminded that any such purchase or subscription must not be made on the basis of the information contained in this Presentation but are referred to the entire body of the amended and restated preliminary prospectus dated on or about November 14, 2012 (the Prospectus ). The Prospectus, which contains important information relating to these securities, has been filed with securities commissions or similar authorities in certain jurisdictions of Canada. The Prospectus is still subject to completion or amendment. Copies of the Prospectus may be accessed through SEDAR at There will not be any sale or any acceptance of an offer to buy the securities until a receipt for the final prospectus has been issued. The information contained in this Presentation is derived solely from the Prospectus and does not purport to be all-inclusive or to contain all the information that an investor may desire to have in evaluating whether or not to make an investment in the Company. The information is qualified entirely by reference to the Prospectus. This Presentation is being supplied to you solely for your information and may not be reproduced, further distributed or published in whole or in part by any other person. Neither this Presentation nor any copy of it may be taken or transmitted into or distributed any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of national securities law. No representation or warranty, express or implied, is made or given by or on behalf of the Company or any of the directors, officers or employees of any such entities as to the accuracy, completeness or fairness of the information or opinions contained in this Presentation and no responsibility or liability is accepted by any person for such information or opinions. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the attendees with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation that may become apparent. The information and opinions contained in this Presentation are provided as at the date of this Presentation. The contents of this Presentation are not to be construed as legal, financial or tax advice. Each prospective investor should contact his, her or its own legal adviser, independent financial adviser or tax adviser for legal, financial or tax advice. Certain statements in this presentation about the Corporation and Kruger Products L.P. ( KPLP ) as it relates to their current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements or any other future events or developments constitute forward-looking statements. The words may, will, would, should, could, expects, plans, intends, trends, indications, anticipates, believes, estimates, predicts, likely or potential or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. The forward-looking information is based on certain key expectations and assumptions made by the Corporation or KPLP, including expectations and assumptions concerning the closing of the initial public offering ( Offering ), the completion of the TAD Project (see page 22) on time and within budget, continued growth of the U.S. private label market and demand for TAD products in the U.S., orders for the TAD machine s products, the amount and timing of distributions made by KPLP, Kruger Inc. s ( Kruger ) cash requirements and expected savings from the Business Rationalization Project. The financial outlook that KPLP Management provides in the Prospectus concerning the potential incremental EBITDA generated by the TAD Project by 2017 may be considered forward-looking information and is based on additional key expectations and assumptions, including but not limited to (i) limited incremental overhead relating to the operation of the TAD machine and distribution and sale of products, (ii) the TAD machine operating at near full capacity and products being sold at prices consistent with current market prices, adjusted for inflation, (iii) a cost of pulp and energy and a selling price of finished products based on recent prices, adjusted for inflation, (iv) Canadian and United States currencies at parity, and (v) the timely completion of the TAD Project within budget. Although the Corporation and KPLP believe that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information since no assurance can be given that such expectations and assumptions will prove to be correct. Additional information on the expectations and assumptions on which such forward-looking information is based, as well as known and unknown risks that could affect Corporation s operations, financial results or distribution levels, are included in KPT s Prospectus filed on or about November 14, 2012 as referenced above. Unless otherwise stated, references in this presentation to market shares or KPT s market leadership are based on ACNielsen dollar market share data and management estimates. See Market and Industry Data section of the Prospectus. 3

4 KPLP INVESTMENT HIGHLIGHTS Canada s #1 tissue company with leading brands Strong free cash flow profile - initial dividend yield of 3.6% - 4.0% Strong customer relationships with compelling retail proposition Well located and efficient infrastructure Experienced management team with track record of EBITDA growth Successful US platform with significant potential upside from TAD Project 4

5 KPLP CORPORATE TIMELINE A Leader in the Tissue Industry Scott Paper Limited Commences Operations Kruger acquires 100% of Scott Paper Limited from KC for $450 million Acquisition of Memphis Plant Begins transitioning the KC brands Successfully completes transition of KC brands Commences TAD Project Business Rationalization Project

6 KPLP BUSINESS OVERVIEW LTM Adj. Revenue: $903 million (1) LTM Adj. EBITDA: $129 million (1) CONSUMER AWAY - F R O M - H O M E (1) 52 weeks ended September 23, 2012; as defined in the Prospectus (also see Prospectus for reconciliations to most comparable IFRS measure). 6

7 KPLP CANADA S LEADING TISSUE COMPANY Bathroom Tissue (Dollar Market Share in Parentheses) Facial Tissue (Dollar Market Share in Parentheses) Paper Towels (Dollar Market Share in Parentheses) #2 (19.8%) #3 (16.0%) #4 (4.7%) #3 (14.0%) #4 (8.0%) #1 (35.9%) #4 (5.2%) #2 (18.3%) #5 (4.5%) Source: ACNielsen; dollar market share for the 52-week period ended Sept 22,

8 KPLP L E A D I N G B R A N D S CANADIAN BRANDS #1 bathroom tissue dollar market share since 2000 #1 facial tissue dollar market share since 2005 #2 paper towel dollar market share since % Premium Quality. 100% Recycled Paper. US BRANDS TOP RANKED bathroom tissue in terms of consumer value by a leading consumer magazine Source: ACNielsen dollar market share data. 8

9 KPLP DRIVE MARKETING EXCELLENCE Relevant and differentiated consumer positioning Breakthrough advertising campaigns Emotional connection via key marketing initiatives (sponsorships, fashion show) Consumer analytics Continued brand investment 9

10 KPLP LEADERSHIP POSITION MAINTAINED OVER TIME 1 st BATHROOM TISSUE 1 st FACIAL TISSUE 2 nd PAPER TOWEL Increased 1.4 percentage points since 2006 Increased 9.1 percentage points since 2006 Increased 1.0 percentage points since YTD weeks 2012 ended September 22, YTD weeks 2012 ended September 22, YTD weeks 2012 ended September 22, 2012 Source: ACNielsen dollar market share data. 10

11 KPLP STRONG CUSTOMER/RETAIL RELATIONSHIPS of all branded tissue product sales at the 6 largest Canadian Grocers (1) of all branded tissue product sales in Canada (1) # 1 Vendor in 2010 # 2 Vendor in 2011/2012 out of 20 of the Largest CPG Companies in Canada (2) (1) ACNielsen data, on a dollar basis. (2) Third-party survey evaluating, amongst other things, quality of personnel and services. 11

12 KPLP ONE OF THE LEADERS IN AWAY-FROM-HOME of total Kruger Products L.P. sales Canadian market share (1) (1) Management estimate. 12

13 KPLP MANUFACTURING & DISTRIBUTION C a p a c i t y A c r o s s N o r t h A m e r i c a New Westminster, BC Crabtree, QC C A N A D A Mississauga, ON U N I T E D S T A T E S Sherbrooke, QC Headquarters Manufacturing Facilities Memphis, TN Gatineau, QC

14 S O F T N E S S KPLP TECHNOLOGICAL ADVANTAGE Objective: Optimum Softness while Maximizing Bulk to reduce unit cost LDC SRC TAD Process A significant portion of KPLP s consumer tissue is manufactured using SRC technology Recycled fibre, better quality WC Lower production costs B U L K Note: WC, LDC, SRC and TAD are the acronyms for wet crepe, light dry crepe, single recrepe and through-air-dried, respectively. 14

15 S O F T N E S S KPLP TECHNOLOGICAL ADVANTAGE TAD Through-Air-Dried LDC SRC TAD Process Softer, bulkier, premium products Cost advantage WC B U L K Note: WC, LDC, SRC and TAD are the acronyms for wet crepe, light dry crepe, single recrepe and through-air-dried, respectively. 15

16 KPLP STRONG MANAGEMENT TEAM Mario Gosselin Chief Executive Officer 15 Years in CPG industry Mark Holbrook Chief Financial Officer 26 Years in CPG industry Michel Manseau VP Consumer Sales Canada 24 Years in CPG industry Eric Bisson VP AFH 16 Years with Kruger/KPLP Gordon Goss VP Consumer Business USA & Mexico 21 Years in CPG industry Nancy Marcus VP Marketing 33 Years in CPG industry Dan Clarahan VP US Business Expansion 33 Years in CPG industry Glenn Taylor VP Manufacturing & International 23 Years in CPG industry Wendy Kelley Corporate Secretary & General Counsel Extensive Legal Experience Average of Over 14 Years in the Tissue Industry and Over 19 Years in CPG 16

17 KPLP GROW PROFITABILITY IN CANADA Maintain leading market positions Drive marketing excellence Leverage category expertise and Preferred Vendor Agreements #1 #1 #2 Emphasize innovation and manufacturing efficiency Invest in high return CAPEX 17

18 KPLP SUCCESSFUL US PENETRATION Serve North American retailers Hedge against US dollar fluctuation Acquired White Cloud brand in 2000 Acquired Memphis Plant in 2002 White Cloud sold exclusively at Walmart White Cloud Ultra #1 US bathroom tissue (1) Sales reached $237 M LTM (1) In May 2012, a leading consumer magazine ranked White Cloud Ultra as the number one bathroom tissue in the U.S. in terms of consumer value. 18

19 KPLP TAD TO CAPTURE GROWING PRIVATE LABEL MARKET Estimated U.S. Retailer Private Label Volume Share 18% 22% US Bathroom Tissue Producers & TAD Capacity (1) P Limited Private Label Presence Source: RISI. Private Label Bathroom Tissue TAD Capacity Products only Represents ~3% of the U.S. Bathroom Tissue Market ,000 1,200 1,400 Tissue Capacity ex. TAD Additional Planned TAD Capacity Installed TAD Capacity Private Label Production (1) Based on RISI data, except for private label production information, which is based on KPLP Management estimates. For Georgia-Pacific, approximately 130,000 tonnes of the planned TAD capacity shown was still LDC tonnage as of December 31,

20 KPLP GROW IN THE US PREMIUM PRIVATE LABEL MARKET $60 MILLION EBITDA OPPORTUNITY BY 2017 (1) US$322 million project 60,000 MT TAD capacity Superior profitability Provide highest level of quality to North American retailers Proven technology On-time and on-budget (1) This estimate of future incremental EBITDA for KPLP by 2017 (the year in which the TAD paper machine is expected to reach its full potential) may be considered forward-looking information and is based upon certain key assumptions which are set out on page 2 of this presentation. These factors could cause the actual contribution to EBITDA by the TAD Project by 2017 to differ materially from the amount set forth in the foregoing estimate. 20

21 KPLP PRODUCT LINE EXTENSIONS Extension of the White Cloud brand Expand into additional categories Considering paper towels, napkins and wipes 21

22 KPLP STRONG HISTORICAL FINANCIAL PERFORMANCE Consolidated Revenue (C$ millions) $461 $518 $543 $590 $616 $619 $703 $765 $773 $811 $870 $901 $898 $893 $921 $ weeks 52 weeks ended ended September September 23, , 2012 (Adjusted) (1) (1) In connection with the Business Rationalization Project, management expects parent roll revenue to decline by $20.0 million ($1.7 million of which had been realized as of Sept. 23, 2012). 22

23 KPLP STRONG HISTORICAL FINANCIAL PERFORMANCE Consolidated EBITDA (1) (C$ millions) Acquired the business US expansion (Acquired Memphis Plant in 2002) $114 Brand transition (marketing investments) $142 Post transition growth (After payment of a management fee of approximately $9 million paid by KPLP to Kruger Inc.) (2) $113 $113 $129 $92 $86 $88 $90 $84 $93 $93 $82 $63 $60 $ weeks (1) As defined in the Prospectus (also see Prospectus for most comparable IFRS / Canadian GAAP measure). (2) KPLP began paying a management fee of approximately $9 million to Kruger Inc. in The figures shown prior to 2009 have not been adjusted to reflect such management fee. ended September 23, weeks ended September 23, 2012 (Adjusted) 23

24 KPLP LTM ADJUSTED EBITDA & BUSINESS RATIONALIZATION PROJECT LTM Adjusted EBITDA (1) (C$ millions) Business Rationalization Project (C$ millions) LTM EBITDA (1) $112.6 Business Rationalization Project $9.0 Management Fee Reduction $5.4 (2) One-Time Reorganization / IPO Costs $1.6 TAD Project Start-up Costs $2.9 Public Company Costs ($2.8) LTM Adjusted EBITDA $128.8 Completed in September 2012 Closed part of the New Westminster plant Elimination of certain head office/plant positions Expected annual cost savings of $11.9 million $2.9 million realized year to date (1) 52 weeks ended September 23, 2012; as defined in the Prospectus (also see Prospectus for reconciliations to most comparable IFRS measure). (2) Adjusted to reflect a $5.4 million reduction in the management fee paid by KPLP to Kruger Inc. Under the terms of the Management Services Agreement, Kruger Inc. charged KPLP a management fee of $9.4 million for the 52 weeks ended September 23, 2012, however, in connection with the Offering, the fee will be reduced to $4.0 million. 24

25 KPLP FREE CASH FLOW PROFILE Stable industry demand Pulp price increases generally passed on to customers High plant utilization Low maintenance CAPEX $141 Cash Flow from Operations and Net Capital Expenditures $126 $147 $44 $73 $60 $23 $25 $22 $ weeks 52 weeks Cash Flow from Operating Activities less Cash Interest Expense ended September 23, 2012 Investment in Property, Plant and Equipment ex. TAD Project, less proceeds from sale of Property, Plant and Equipment ended September 23, 2012 (Adjusted) Initial annual dividend of 72 /share, initial yield of 3.6% - 4.0% 25

26 KPLP CORPORATE STRUCTURE KRUGER INC. (1) PUBLIC INVESTORS 100% KP TISSUE INC. Canada 16.9% KPGP INC. Canada <.01% KRUGER PRODUCTS L.P. Quebec 83.1% K.T.G. (USA) INC. Kruger Products L.P. is the operating company KP Tissue Inc. is the publicly traded entity (1) Directly and/or indirectly through one or more subsidiaries. 26

27 KPLP STRONG BALANCE SHEET Pro Forma Capitalization (1) (C$ millions) KPLP ex. KTG Opening Balance IPO Adjustments Closing Balance $195 million Senior Credit Facility $10.0 ($10.0) $0.0 IQ Loan $3.1 $3.1 Nordea Loan $40.7 $40.7 Senior Unsecured Notes $175.0 $175.0 Less: Deferred Financing Fees ($6.8) ($6.8) TOTAL DEBT $222.1 $212.1 Less: Cash at KPLP ex. KTG ($16.8) ($28.6) ($45.4) Net Debt ex. KTG $205.2 $166.6 Net Debt / LTM Adj. EBITDA ex. KTG 1.7x 1.4x KTG TAD Credit Facility $83.0 $83.0 Deferred Financing Fees ($5.8) ($5.8) Cash at KTG ($11.9) ($50.0) ($61.9) (2) (1) Gross debt balances presented as of September 23, (2) Will be used to fund construction of the TAD Project. Note that cash proceeds may temporarily reside at KPLP bank accounts not held in the name of KTG. 27

28 KPLP INVESTMENT HIGHLIGHTS Canada s #1 tissue company with leading brands Strong free cash flow profile - initial dividend yield of 3.6% - 4.0% Strong customer relationships with compelling retail proposition Well located and efficient infrastructure Experienced management team with track record of EBITDA growth Successful US platform with significant potential upside from TAD Project 28

29 INVESTOR PRESENTATION January 2013